HIV-1 viral diversity and its implications for viral load testing: Review of current platforms

International Journal of Infectious Diseases

Volumn 15, Issue 10, 2011, Pages

  Luft, LeeAnne M ^a   Gill, M John ^a   Church, Deirdre L ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Genotype; Global epidemic; HIV viral load; Subtype diversity

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS DNA; VIRUS RNA;

CLINICAL EFFECTIVENESS; DIAGNOSTIC ACCURACY; DISEASE COURSE; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MICROBIAL DIVERSITY; PATIENT CARE; PHLEBOTOMY; REVIEW; RNA EXTRACTION; SENSITIVITY AND SPECIFICITY; TANDEM REPEAT; TRAVEL; TREATMENT RESPONSE; VALIDITY; VIRUS GENE; VIRUS LOAD; VIRUS REPLICATION;

GENETIC VARIATION; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; VIRAL LOAD;

EID: 80053245037     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2011.05.013     Document Type: Review

References (105)

1. Korenromp E.L., Williams B.G., Schmid G.P., Dye C. Clinical prognostic value of RNA viral load and CD4 cell counts during untreated HIV-1 infection-a quantitative review. PLoS One 2009, 4:e5950.
2. Kredo T., Van der Walt J.S., Siegfried N., Cohen K. Therapeutic drug monitoring of antiretrovirals for people with HIV. Cochrane Database Syst Rev 2009, (3):CD007268.
3. Mellors J.W., Rinaldo C.R., Gupta P., White R.M., Todd J.A., Kinsley L.A. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
4. Sivapalasingam S., Wangechi B., Marshed F., Laverty M., Essajee S., Holzman R.S., et al. Monitoring virologic responses to antiretroviral therapy in HIV-infected adults in Kenya: evaluation of a low-cost viral load assay. PLoS One 2009, 4:e6828.
5. Gupta R.K., Hill A., Sawyer A.W., Cozzi-Lepri A., von Wyl V., Yerly S., et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009, 9:409-417.
6. Hirsch M.S., Gunthard H.F., Schapiro J.M., Brun-Vezinet F., Clotet B., Hammer S.M., et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Top HIV Med 2008, 16:266-285.
7. Kumwenda N.I., Hoover D.R., Mofenson L.M., Thigpen M.C., Kafulafula G., Li Q., et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 2008, 359:119-129.
8. Zhang M., Versalovic J. HIV update. Diagnostic tests and markers of disease progression and response to therapy. Am J Clin Pathol 2002, 118(Suppl):S26-32.
9. Baldanti F., Paolucci S., Gulminetti R., Brandolini M., Barbarini G., Maserati R. Early emergences of raltegravir resistance mutations in patients receiving HAART salvage regimens. J Med Virol 2010, 82:116-122.
10. Saag M.S., Holodniy M., Kuritzkes D.R., O'Brien W.A., Coombs R., Poscher M.E., et al. HIV viral load markers in clinical practice. Nat Med 1996, 2:625-629.
11. Markowitz M., Nguyen B.Y., Gotuzzo E., Mendo F., Ratanasuwan W., Kovacs C., et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr 2009, 52:350-356.
12. Schooley R.T. Correlation between viral load measurements and outcome in clinical trials of antiviral drugs. AIDS 1995, 9(Suppl 2):S15-S19.
13. van Luin M., Colbers A., Verwey-van Wissen C.P., van Ewijk-Beneken-Kolmer E.W., van der Kolk M., Hoitsma A., et al. The effect of raltegravir on the glucuronidation of lamotrigine. J Clin Pharmacol 2009, 49:1220-1227.
14. Yazdanpanah Y., Fagard C., Descamps D., Taburet A.M., Colin C., Roquebert B., et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 2009, 49:1441-1449.
15. Cartwright C.P. The changing epidemiology of HIV/AIDS at a Minnesota hospital: impact of demographic change and viral diversity. J Med Virol 2006, 78(Suppl 1):S19-21.
16. Krentz H., Gill M.J. The five-year impact of an evolving global epidemic, changing migration patterns, and policy changes in a regional Canadian HIV population. Health Policy 2009, 90:296-302.
17. Parczewski M., Leszczyszyn-Pynka M., Bander D., Urbanska A., Stanczak G., Boron-Kaczmarska A. Characteristics of HIV-1 non-B subtype infections in Northwest Poland. J Med Virol 2010, 82:1306-1313.
18. Parker M.M., Gordon D., Reilly A., Horowitz H.W., Waters M., Bennett R., et al. Prevalence of drug-resistant and nonsubtype B HIV strains in antiretroviral-naive, HIV-infected individuals in New York State. AIDS Patient Care STDS 2007, 21:644-652.
19. Semaille C., Barin F., Cazein F., Pillonel J., Lot F., Brand D., et al. Monitoring the dynamics of the HIV epidemic using assays for recent infection and serotyping among new HIV diagnoses: experience after 2 years in France. J Infect Dis 2007, 196:377-383.
20. Tatt I.D., Barlow K.L., Clewley J.P., Gill O.N., Parry J.V. Surveillance of HIV-1 subtypes among heterosexuals in England and Wales, 1997-2000. J Acquir Immune Defic Syndr 2004, 36:1092-1099.
21. Hammer S.M., Eron J.J., Reiss P., Schooley R.T., Thompson M.A., Walmsley S., et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008, 300:555-570.
22. Brennan C.A., Bodelle P., Coffey R., Harris B., Holzmayer V., Luk K.C., et al. HIV global surveillance: foundation for retroviral discovery and assay development. J Med Virol 2006, 78(Suppl 1):S24-S29.
23. Calmy A., Ford N., Hirschel B., Reynolds S.J., Lynen L., Goemaere E., et al. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis 2007, 44:128-134.
24. Preiser W., Drexler J.F., Drosten C. HIV-1 viral load assays for resource-limited settings: clades matter. PLoS Med 2006, 3:e538.
25. Damond F., Collin G., Descamps D., Matheron S., Pueyo S., Taieb A., et al. Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay. J Clin Microbiol 2005, 43:4234-4236.
26. Soriano V., Gomes P., Heneine W., Holguin A., Doruana M., Antunes R., et al. Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. J Med Virol 2000, 61:111-116.
27. Damond F., Gueudin M., Pueyo S., Farfara I., Robertson D.L., Deschamps D., et al. Plasma RNA viral load in human immunodeficiency virus type 2 subtype A and subtype B infections. J Clin Microbiol 2002, 40:3654-3659.
28. Fonquernie L., Eholie S.P., Damond F., Lacombe K., Girard P.M. Failure of HIV-2 viral load assay in a severely immunodeficient patient: clinical and therapeutic management issues. Trans R Soc Trop Med Hyg 2006, 100:282-284.
29. Damond F., Benard A., Ruelle J., Alabi A., Kupfer B., Gomes P., et al. Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006. J Clin Microbiol 2008, 46:2088-2091.
30. Plantier J.C., Leoz M., Dickerson J.E., De Oliveira F., Cordonnier F., Lemee V., et al. A new human immunodeficiency virus derived from gorillas. Nat Med 2009, 15:871-872.
31. Hemelaar J., Gouws E., Ghys P.D., Osmanov S. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011, 25:679-689.
32. Pasquier C., Millot N., Njouom R., Sandres K., Cazabat M., Puel J., et al. HIV-1 subtyping using phylogenetic analysis of pol gene sequences. J Virol Methods 2001, 94:45-54.
33. Robertson D.L., Anderson J.P., Bradac J.A., Carr J.K., Foley B., Funkhouser R.K., et al. HIV-1 nomenclature proposal. Science 2000, 288:55-56.
34. Michael N.L. Host genetic influences on HIV-1 pathogenesis. Curr Opin Immunol 1999, 11:466-474.
35. Roberts J.D., Bebenek K., Kunkel T.A. The accuracy of reverse transcriptase from HIV-1. Science 1988, 242:1171-1173.
36. Blackard J.T., Cohen D.E., Mayer K.H. Human immunodeficiency virus superinfection and recombination: current state of knowledge and potential clinical consequences. Clin Infect Dis 2002, 34:1108-1114.
37. Robertson D.L., Sharp P.M., McCutchan F.E., Hahn B.H. Recombination in HIV-1. Nature 1995, 374:124-126.
38. Hemelaar J., Gouws E., Ghys P.D., Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006, 20:W13-23.
39. Tatt I.D., Barlow K.L., Nicoll A., Clewley J.P. The public health significance of HIV-1 subtypes. AIDS 2001, 15(Suppl 5):S59-S71.
40. Taylor B.S., Hammer S.M. The challenge of HIV-1 subtype diversity. N Engl J Med 2008, 359:1965-1966.
41. Katzenstein D., Ogden R. Among the devils in the details are protease sequence, susceptibility, and structure in CRF02_AG viruses. Clin Infect Dis 2005, 41:252-254.
42. Kondo M., Kawata K., Ito A., Saito T., Imai M. [Quantitation of viral load in patients infected with HIV-1 subtype E or A]. Kansenshogaku Zasshi 1998, 72:609-614.
43. Emery S., Bodrug S., Richardson B.A., Giachetti C., Bott M.A., Panteleeff D., et al. Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clin Microbiol 2000, 38:2688-2695.
44. de La Rosa R., Leal M., Pineda J.A., Dietrich U., Delgado J., Macias J., et al. Low levels of HIV-1 plasma viral load in patients infected with HIV-1 subtype b and advanced immunosuppression. J Infect 2001, 42:4-7.
45. US refuse to issue entry visas to people with HIV/AIDS. Natl AIDS Bull 1991;5:8.
46. Fairchild A.L., Tynan E.A. Policies of containment: immigration in the era of AIDS. Am J Public Health 1994, 84:2011-2022.
47. Bennett D. HIV [corrected] genetic diversity surveillance in the United States. J Infect Dis 2005, 192:4-9.
48. Thomson M.M., Najera R. Increasing HIV-1 genetic diversity in Europe. J Infect Dis 2007, 196:1120-1124.
49. Lospitao E., Alvarez A., Soriano V., Holguin A. HIV-1 subtypes in Spain: a retrospective analysis from 1995 to 2003. HIV Med 2005, 6:313-320.
50. Luft LM, Beckthold B, Gill MJ. Increasing HIV subtype diversity in Canadian born patients living in southern Alberta, Canada. J Acquir Immune Defic Syndr 2011.[in press].
51. Preston J. Obama lifts a ban on entry into U. S. by H.I.V.-positive people. The New York Times. 2009 Oct 30.
52. Shafer R.W. Rationale and uses of a public HIV drug-resistance database. J Infect Dis 2006, 194(Suppl 1):S51-S58.
53. Campbell T.B. Are all HIV type 1 strains created equal? Clin Infect Dis 2006, 42:853-854.
54. Yang C., Pieniazek D., Owen S.M., Fridlund C., Nkengasong J., Mastro T.D., et al. Detection of phylogenetically diverse human immunodeficiency virus type 1 groups M and O from plasma by using highly sensitive and specific generic primers. J Clin Microbiol 1999, 37:2581-2586.
55. Ruelle J., Jnaoui K., Lefevre I., Lamarti N., Goubau P. Comparative evaluation of the VERSANT HIV-1 RNA 1.0 kinetic PCR molecular system (kPCR) for the quantification of HIV-1 plasma viral load. J Clin Virol 2009, 44:297-301.
56. Giordano M., Kelleher T., Colonno R.J., Lazzarin A., Squires K. The effects of the Roche AMPLICOR HIV-1 MONITOR UltraSensitive Test versions 1.0 and 1.5 viral load assays and plasma collection tube type on determination of response to antiretroviral therapy and the inappropriateness of cross-study comparisons. J Clin Virol 2006, 35:420-425.
57. Amellal B., Murphy R., Maiga A., Brucker G., Katlama C., Calvez V., et al. Stability of HIV RNA in plasma specimens stored at different temperatures. HIV Med 2008, 9:790-793.
58. Cassol S., Gill M.J., Pilon R., Cormier M., Voigt R.F., Willoughby B., et al. Quantification of human immunodeficiency virus type 1 RNA from dried plasma spots collected on filter paper. J Clin Microbiol 1997, 35:2795-2801.
59. Fiscus S.A., Brambilla D., Grosso L., Schock J., Cronin M. Quantitation of human immunodeficiency virus type 1 RNA in plasma by using blood dried on filter paper. J Clin Microbiol 1998, 36:258-260.
60. O'Shea S., Mullen J., Corbett K., Chrystie I., Newell M.L., Banatvala J.E. Use of dried whole blood spots for quantification of HIV-1 RNA. AIDS 1999, 13:630-631.
61. Alvarez-Munoz M.T., Zaragoza-Rodriguez S., Rojas-Montes O., Palacios-Saucedo G., Vazquez-Rosales G., Gomez-Delgado A., et al. High correlation of human immunodeficiency virus type-1 viral load measured in dried-blood spot samples and in plasma under different storage conditions. Arch Med Res 2005, 36:382-386.
62. Kane C.T., Ndiaye H.D., Diallo S., Ndiaye I., Wade A.S., Diaw P.A., et al. Quantitation of HIV-1 RNA in dried blood spots by the real-time NucliSENS EasyQ HIV-1 assay in Senegal. J Virol Methods 2008, 148:291-295.
63. Ikomey G.M., Atashili J., Okomo-Assoumou M.C., Mesembe M., Ndumbe P.M. Dried blood spots versus plasma for the quantification of HIV-1 RNA using the manual (PCR-ELISA) Amplicor Monitor HIV-1 Version 1.5 Assay in Yaounde, Cameroon. J Int Assoc Physicians AIDS Care (Chic) 2009, 8:181-184.
64. Church D., Gregson D., Lloyd T., Klein M., Beckthold B., Laupland K., et al. Comparison of the RealTime HIV-1, COBAS TaqMan 48 v1.0, EasyQ v1. 2, and VERSANT v3. 0 assays for determination of HIV-1 viral loads in a cohort of Canadian patients with diverse HIV subtype infections. J Clin Microbiol 2011, 49:118-124.
65. Claassen M., van Zyl G.U., Preiser W. Extraction buffer contaminated bacterially as a cause of invalid HIV-1 viral load results on the NucliSens EasyQ system. J Virol Methods 2008, 150:80-81.
66. Lee S., Wood O., Taffs R.E., Hu J., Machuca A., Vallejo A., et al. Development and evaluation of HIV-1 subtype RNA panels for the standardization of HIV-1 NAT assays. J Virol Methods 2006, 137:287-291.
67. Michael N.L., Herman S.A., Kwok S., Dreyer K., Wang J., Christopherson C., et al. Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes. J Clin Microbiol 1999, 37:2557-2563.
68. Amendola A., Bordi L., Angeletti C., Visco-Comandini U., Abbate I., Cappiello G., et al. Underevaluation of HIV-1 plasma viral load by a commercially available assay in a cluster of patients infected with HIV-1 A/G circulating recombinant form (CRF02). J Acquir Immune Defic Syndr 2002, 31:488-494.
69. Antunes R., Figueiredo S., Bartolo I., Pinheiro M., Rosado L., Soares I., et al. Evaluation of the clinical sensitivities of three viral load assays with plasma samples from a pediatric population predominantly infected with human immunodeficiency virus type 1 subtype G and BG recombinant forms. J Clin Microbiol 2003, 41:3361-3367.
70. Chew C.B., Zheng F., Byth K., Van Asten M., Workman C., Dwyer D.E. Comparison of three commercial assays for the quantification of plasma HIV-1 RNA from individuals with low viral loads. AIDS 1999, 13:1977-1978.
71. Clarke J.R., Galpin S., Braganza R., Ashraf A., Russell R., Churchill D.R., et al. Comparative quantification of diverse serotypes of HIV-1 in plasma from a diverse population of patients. J Med Virol 2000, 62:445-449.
72. Debyser Z., Van Wijngaerden E., Van Laethem K., Beuselinck K., Reynders M., De Clercq E., et al. Failure to quantify viral load with two of the three commercial methods in a pregnant woman harboring an HIV type 1 subtype G strain. AIDS Res Hum Retroviruses 1998, 14:453-459.
73. Gottesman B.S., Grosman Z., Lorber M., Levi I., Shitrit P., Mileguir F., et al. Measurement of HIV RNA in patients infected by subtype C by assays optimized for subtype B results in an underestimation of the viral load. J Med Virol 2004, 73:167-171.
74. Kim J.E., Beckthold B., Chen Z., Mihowich J., Malloch L., Gill M.J. Short communication: identification of a novel HIV type 1 subtype H/J recombinant in Canada with discordant HIV viral load (RNA) values in three different commercial assays. AIDS Res Hum Retroviruses 2007, 23:1309-1313.
75. Parekh B., Phillips S., Granade T.C., Baggs J., Hu D.J., Respess R. Impact of HIV type 1 subtype variation on viral RNA quantitation. AIDS Res Hum Retroviruses 1999, 15:133-142.
76. Gill MJ, Beckthold B, Church DL, Kim J. The impact of viral diversity on viral load quantifications. Poster exhibition: 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Abstract No. TUPEB059. Sydney, Australia, July 24, 2007.
77. O'Bryan T., Jadavji T., Kim J., Gill M.J. An avoidable transmission of HIV from mother to child. CMAJ 2011, 183:690-692.
78. Crump J.A., Scott L.E., Msuya E., Morrissey A.B., Kimaro E.E., Shao J.F., et al. Evaluation of the Abbott m2000rt RealTime HIV-1 assay with manual sample preparation compared with the ROCHE COBAS AmpliPrep/AMPLICOR HIV-1 MONITOR v1.5 using specimens from East Africa. J Virol Methods 2009, 162:218-222.
79. Scott L.E., Noble L.D., Moloi J., Erasmus L., Venter W.D., Stevens W. Evaluation of the Abbott m2000 RealTime human immunodeficiency virus type 1 (HIV-1) assay for HIV load monitoring in South Africa compared to the Roche Cobas AmpliPrep-Cobas Amplicor, Roche Cobas AmpliPrep-Cobas TaqMan HIV-1, and BioMerieux NucliSENS EasyQ HIV-1 assays. J Clin Microbiol 2009, 47:2209-2217.
80. Swanson P., Huang S., Abravaya K., de Mendoza C., Soriano V., Devare S.G., et al. Evaluation of performance across the dynamic range of the Abbott RealTime HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses. J Virol Methods 2007, 141:49-57.
81. Gueudin M., Plantier J.C., Lemee V., Schmitt M.P., Chartier L., Bourlet T., et al. Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes. J Acquir Immune Defic Syndr 2007, 44:500-505.
82. Holguin A., Lopez M., Molinero M., Soriano V. Performance of three commercial viral load assays, VERSANT human immunodeficiency virus type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1. 2, testing HIV-1 non-B subtypes and recombinant variants. J Clin Microbiol 2008, 46:2918-2923.
83. Swanson P., Holzmayer V., Huang S., Hay P., Adebiyi A., Rice P., et al. Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from London: comparison to VERSANT HIV-1 RNA 3.0, AMPLICOR HIV-1 MONITOR v1. 5, and LCx HIV RNA Quantitative assays. J Virol Methods 2006, 137:184-192.
84. Xu S., Song A., Nie J., Li A., Li J., Bao Z., et al. Comparative evaluation of the COBAS AmpliPrep/COBAS TaqMan HIV type 1 test (CAP/CTM) and VERSANT HIV type 1 RNA 3.0 assay (bDNA) for quantifying HIV type 1 viral loads in China. AIDS Res Hum Retroviruses 2008, 24:1365-1373.
85. Alaeus A., Lidman K., Sonnerborg A., Albert J. Subtype-specific problems with quantification of plasma HIV-1 RNA. AIDS 1997, 11:859-865.
86. Burgisser P., Vernazza P., Flepp M., Boni J., Tomasik Z., Hummel U., et al. Performance of five different assays for the quantification of viral load in persons infected with various subtypes of HIV-1. Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2000, 23:138-144.
87. Jenny-Avital E.R., Beatrice S.T. Erroneously low or undetectable plasma human immunodeficiency virus type 1 (HIV-1) ribonucleic acid load, determined by polymerase chain reaction, in West African and American patients with non-B subtype HIV-1 infection. Clin Infect Dis 2001, 32:1227-1230.
88. Badreddine S., Smith K., van Zyl H., Bodelle P., Yamaguchi J., Swanson P., et al. Identification and characterization of HIV type 1 subtypes present in the Kingdom of Saudi Arabia: high level of genetic diversity found. AIDS Res Hum Retroviruses 2007, 23:667-674.
89. Brennan C.A., Brites C., Bodelle P., Golden A., Hackett J., Holzmayer V., et al. HIV-1 strains identified in Brazilian blood donors: significant prevalence of B/F1 recombinants. AIDS Res Hum Retroviruses 2007, 23:1434-1441.
90. Holguin A., Alvarez A., Soriano V. Heterogeneous nature of HIV-1 recombinants spreading in Spain. J Med Virol 2005, 75:374-380.
91. Luk K.C., Holzmayer V., Yamaguchi J., Swanson P., Brennan C.A., Ngansop C., et al. Near full-length genome characterization of three additional HIV type 1 CRF13_cpx strains from Cameroon. AIDS Res Hum Retroviruses 2007, 23:297-302.
92. Yang C., Li M., Mokili J.L., Winter J., Lubaki N.M., Mwandagalirwa K.M., et al. Genetic diversification and recombination of HIV type 1 group M in Kinshasa, Democratic Republic of Congo. AIDS Res Hum Retroviruses 2005, 21:661-666.
93. Tang N., Huang S., Salituro J., Mak W.B., Cloherty G., Johanson J., et al. A RealTime HIV-1 viral load assay for automated quantitation of HIV-1 RNA in genetically diverse group M subtypes A-H, group O and group N samples. J Virol Methods 2007, 146:236-245.
94. Colson P., Solas C., Moreau J., Motte A., Henry M., Tamalet C. Impaired quantification of plasma HIV-1 RNA with a commercialized real-time PCR assay in a couple of HIV-1-infected individuals. J Clin Virol 2007, 39:226-229.
95. Gottesman B.S., Grossman Z., Lorber M., Levi I., Shitrit P., Katzir M., et al. Comparative performance of the Amplicor HIV-1 Monitor Assay versus NucliSens EasyQ in HIV subtype C-infected patients. J Med Virol 2006, 78:883-887.
96. Plantier J.C., Gueudin M., Damond F., Braun J., Mauclere P., Simon F. Plasma RNA quantification and HIV-1 divergent strains. J Acquir Immune Defic Syndr 2003, 33:1-7.
97. Bikandou B., Ndoundou-Nkodia M.Y., Niama F.R., Ekwalanda M., Obengui O., Taty-Taty R., et al. Genetic subtyping of gag and env regions of HIV type 1 isolates in Republic of Congo. AIDS Res Hum Retroviruses 2004, 20:1005-1009.
98. Rouet F., Foulongne V., Viljoen J., Steegen K., Becquart P., Valea D., et al. Comparison of the generic HIV viral load assay with the Amplicor HIV-1 monitor v1.5 and Nuclisens HIV-1 EasyQ v1.2 techniques for plasma HIV-1 RNA quantitation of non-B subtypes: the Kesho Bora preparatory study. J Virol Methods 2010, 163:253-257.
99. Rouet F., Menan H., Viljoen J., Ngo-Giang-Huong N., Mandaliya K., Valea D., et al. In-house HIV-1 RNA real-time RT-PCR assays: principle, available tests and usefulness in developing countries. Expert Rev Mol Diagn 2008, 8:635-650.
100. Rouet F., Rouzioux C. The measurement of HIV-1 viral load in resource-limited settings: how and where? Clin Lab 2007, 53:135-148.
101. Rouet F., Rouzioux C. HIV-1 viral load testing cost in developing countries: what's new? Expert Rev Mol Diagn 2007, 7:703-707.
102. Braun J., Plantier J.C., Hellot M.F., Tuaillon E., Gueudin M., Damond F., et al. A new quantitative HIV load assay based on plasma virion reverse transcriptase activity for the different types, groups and subtypes. AIDS 2003, 17:331-336.
103. Schupbach J. Viral RNA and p24 antigen as markers of HIV disease and antiretroviral treatment success. Int Arch Allergy Immunol 2003, 132:196-209.
104. Lombart J.P., Vray M., Kafando A., Lemee V., Ouedraogo-Traore R., Corrigan G.E., et al. Plasma virion reverse transcriptase activity and heat dissociation-boosted p24 assay for HIV load in Burkina Faso. West Africa AIDS 2005, 19:1273-1277.
105. Clancy A., Crowley B., Niesters H., Herra C. The development of a qualitative real-time PCR assay for the detection of hepatitis V virus. Eur J Clin Microbiol Infect Dis 2008, 27:1177-1182.